Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 January 2019 | Story Charlene Stanley | Photo Anja Aucamp
Dr Allessandra Kim Heggenstaller
Dr Allessandra Kim Heggenstaller’s doctoral thesis found that cosmetic surgery can lead to an enhanced sense of empowerment.

With human rights at the centre of our modern society’s psyche, the concept of women taking ownership of their own bodies is often interpreted as standing up against all forms of abuse as well as celebrating their own physical uniqueness.

But what about the interpretation that ownership also gives you the right to alter your physical appearance through cosmetic surgery?

The stigma traditionally surrounding cosmetic surgery which is purely done to correct a perceived physical flaw or shortcoming and not for health reasons, has always intrigued Alessandra Kim Heggenstaller. So much so, that the 31-year-old Sociology graduate made it the topic of her doctoral thesis (The role of cosmetic surgery in the embodied experience of female beauty).

 

Beauty and success

“Nowadays, the concept of human ‘beauty’ is intricately linked to that of identity: beauty is seen as

bringing success in occupation, love, and marriage. Accordingly, beauty is often treated as a commodity – social status is attributed to it, and negotiated with it,” says Heggenstaller.

She wanted to test the prevailing negative perception that women who opt for corrective surgery are vain and superficial and are motivated by their desire to fit into a stereotype of ‘the perfect female body’.

 

Surgery a last resort

In her research, Heggenstaller interviewed 10 Free State women who had cosmetic interventions.

The women were from various ages and backgrounds. However, Heggenstaller found certain commonalities:

“None of them did it for a male partner or to fit a perceived stereotype. All of them had done intensive research beforehand and for each of them surgery was really a last resort,” she says.

She found that the women’s main motivation was that they didn’t ‘feel at home’ in their own

bodies because of the perceived shortcoming.

“The study found that a cosmetic procedure was an action and choice that began a journey of change and self-discovery. When the physical body portrays a more accurate image of how the individual feels, she engages her lifeworld and social environment with an enhanced sense of empowerment,” says Heggenstaller.

 

No regrets

“It was also significant to hear that not one of my case studies had any regrets about opting for surgery. In fact, they all felt that they should have done it sooner.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept